Journal
STEM CELLS
Volume 24, Issue 5, Pages 1174-1184Publisher
WILEY
DOI: 10.1634/stemcells.2005-0519
Keywords
FMS-like tyrosine kinase 3; hematopoiesis; acute myeloid leukemia; internal tandem duplication; small molecule inhibitor
Categories
Funding
- NCI NIH HHS [CA108545] Funding Source: Medline
- NHLBI NIH HHS [HL75826] Funding Source: Medline
- PHS HHS [RHL083077A] Funding Source: Medline
Ask authors/readers for more resources
Ligand-mediated activation of the FMS-like tyrosine kinase 3 (FLT3) receptor is important for normal proliferation of primitive hematopoietic cells. However, activating mutations in FLT3 induce ligand-independent downstream signaling that promotes oncogenesis through pathways involved in proliferation, differentiation, and survival. FLT3 mutations are identified as the most frequent genetic abnormality in acute myeloid leukemia and are also observed in other leukemias. Multiple small-molecule inhibitors are under development to target aberrant FLT3 activity that confers a poor prognosis in patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available